AstraZeneca (AZN) Trading Down 0%

AstraZeneca plc (LON:AZN)’s share price fell 0% during mid-day trading on Monday . The company traded as low as GBX 5,145.10 ($69.77) and last traded at GBX 5,153 ($69.88). 1,360,345 shares traded hands during mid-day trading, a decline of 22% from the average session volume of 1,740,000 shares. The stock had previously closed at GBX 5,153 ($69.88).

Several equities analysts have issued reports on the stock. UBS Group set a GBX 4,550 ($61.70) target price on shares of AstraZeneca and gave the company a “neutral” rating in a research note on Monday. Jefferies Group restated a “hold” rating and set a GBX 5,100 ($69.16) target price on shares of AstraZeneca in a research note on Monday, November 6th. Morgan Stanley set a GBX 4,700 ($63.74) target price on shares of AstraZeneca and gave the company a “neutral” rating in a research note on Friday, October 20th. Deutsche Bank restated a “buy” rating and set a GBX 5,600 ($75.94) target price on shares of AstraZeneca in a research note on Wednesday, October 11th. Finally, JPMorgan Chase & Co. set a GBX 4,500 ($61.03) target price on shares of AstraZeneca and gave the company a “neutral” rating in a research note on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the stock. AstraZeneca presently has a consensus rating of “Hold” and a consensus price target of GBX 5,200.82 ($70.53).

The company has a market cap of $65,150.00 and a price-to-earnings ratio of 2,501.46.

TRADEMARK VIOLATION NOTICE: This piece of content was published by BBNS and is owned by of BBNS. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/astrazeneca-azn-trading-down-0/1819270.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.